Research programme: androgen receptor antagonists - Bristol-Myers Squibb

Drug Profile

Research programme: androgen receptor antagonists - Bristol-Myers Squibb

Alternative Names: BMS 501949; BMS 647176; BMS-779333

Latest Information Update: 07 May 2010

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Aza compounds; Heterocyclic bicyclo compounds; Hydantoins; Small molecules
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 21 Apr 2010 Pharmacodynamics data from preclinical studies in Prostate cancer presented at the 101st Annual Meeting of the American Association for Cancer Research
  • 15 Jan 2008 Preclinical development is ongoing
  • 13 Apr 2004 Preclinical trials in Prostate cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top